Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4 + CTL epitope located at the transmembrane-cytoplasmic junction

Abstract

The glycoprotein D of HSV-2 (gD2) is currently a leading candidate vaccine target for genital herpes vaccines as both cellular and humoral responses can be generated against it. However, little is known about how vaccine composition will affect T cell epitope selection. A panel of 15-mer peptides (with 11 amino acid overlap) spanning full-length gD2 was used to investigate the fine specificity of T cell responses to gD2 as well as the role of vaccine composition on epitope selection. Spleen cells from BALB/c mice (H-2 d) immunized with gD2, formulated with or without AlPO 4 and/or IL-12, were stimulated in vitro with overlapping gD2 peptides. Cellular responses (lymphoproliferation and IFN-γ expression) were mapped to four epitopes within the gD2 molecule: gD2 49–63, gD2 105–119, gD2 245–259, and gD2 333–347. CTL analysis of these four epitopes indicated that not all of them could serve as a CTL epitope. Mice immunized with gD2 expressed from a viral vector mounted CTL responses primarily to one epitope located in the extracellular domain of gD2 (gD2 245–259). More importantly, mice immunized with gD2 co-administered with IL-12 mounted CTL responses to an additional epitope located at the transmembrane-cytoplasmic junction of gD2 (gD2 333–347). The location of this novel epitope emphasizes the benefit of using full-length versions of glycoproteins when designing vaccine components.